comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 03:32:08 - browse：45

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

WSS

The strategy behind pharma's lawsuits over drug pricing reform

STAT Boddities: What happens to the brain when we get scared?

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Long Covid research funding gets a major boost from NIH

Cloning humans is technically possible. It's curious no one has tried

STAT's guide to the next generation of CAR

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Colonoscopy at 40? Study finds a possible benefit

Anesthesiologist group: stop taking Ozempic before surgery

Here’s what’s in the FDA plan to include pregnant women in clinical trials

In Memoriam: Notable people who died in 2023

The science behind Janet Jackson's pregnancy at 49

Novavax promises a turnaround & Lilly roils the obesity market

Why drug prescriptions should include diagnoses

Trump demands the U.S. pay no more for drugs than other countries … again

Cloning humans is technically possible. It's curious no one has tried

entertainment

Abbott's new heart device gets FDA advisory panel nod

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Gene therapy has helped boys walk. Can scientists keep it that way?

Cloning humans is technically possible. It's curious no one has tried

The story of mRNA: From a loose idea to a tool that may help curb Covid

Readout Newsletter: Amylyx, Aurinia, and IQVIA

knowledge

focus

focus

hotspot